Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum OrganiGram Holdings Inc T.OGI

Alternate Symbol(s):  OGI

Organigram Holdings Inc. operates through its subsidiaries. The Company’s major wholly owned subsidiaries include Organigram Inc., 10870277 Canada Inc., The Edibles and Infusions Corporation (EIC), and Laurentian Organic Inc. (Laurentian). Organigram Inc. is a licensed producer (LP) of cannabis, cannabis-derived products and cannabis infused edibles in Canada. It is focused on producing... see more

TSX:OGI - Post Discussion

OrganiGram Holdings Inc > Q2 around May 13 ! Looking for better report then....
View:
Post by 1hot-techwoman on Apr 26, 2024 1:03pm

Q2 around May 13 ! Looking for better report then....

When Q1 came out we we trading around $2.68...now its $2.57 going into Q2....Why would they raise $150 Million at $3.23 if they hadnt done there reasearch going forward? Me think Q2 will be good :) IMO


DJ OrganiGram Shares Fall on Loss, Revenue Miss as International Sales Lag in 1Q

Tuesday, February 13, 2024, 10:10 AM ET
 
 	

By Adriano Marchese
 	

OrganiGram Holdings shares were down Tuesday morning after the company reported a loss and lower than expected revenue in its fiscal first quarter as international sales lag.

In recent trading, shares were 7.3% lower to 2.68 Canadian dollars ($1.99).

The Canadian licensed cannabis producer reported a loss of C$15.8 million, compared with an profit of C$5.3 million a year earlier.

The company said that the decline was largely the result of lower gross margin due to the change in fair value of the company's biological assets.

Net revenue fell 16% to C$36.5 million, while analysts expected a slightly less sharp decline to C$37.8 million.

OrganiGram blames the decrease on a reduction in international revenue and medical sales.
Be the first to comment on this post